8-K current report · filed Aug 6, 2026

STAAR SURGICAL CO (STAA) 8-K Current Report: August 6, 2026

Item 5.02Item EX-99.1Item 7.01STAA overview

Short answer

STAAR SURGICAL CO (STAA) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item EX-99.1 (Exhibit EX-99.1), Item 7.01 (Regulation FD Disclosure). Warren Foust appointed CEO and director, effective August 4, 2026, ending interim leadership.

STAAR SURGICAL CO 8-K event analysis

AI summary of each reported item and its exhibits

Item 5.02 · Departure/Election of Directors or Officers

  • Warren Foust appointed CEO and director, effective August 4, 2026, ending interim leadership
  • Foust base salary $730,000 with 100% target bonus on salary earned after February 1, 2026
  • CEO equity package totals 194,794 awards, including 131,830 performance options tied to $50, $75, and $100 share-price hurdles
  • Foust receives 18 months’ base pay and benefits upon qualifying termination, including following a change in control
  • Deborah Andrews remains CFO and becomes EVP, receiving options on 38,111 shares plus RSUs for 4,975 shares

Item 7.01 · Regulation FD Disclosure

  • Board appointed Mr. Foust President and CEO, formalizing leadership succession
  • Mr. Foust added as a new board member, increasing management representation on the Board
  • Ms. Andrews continues as CFO and became Executive Vice President effective August 4, 2026
  • Transition ends Ms. Andrews’ Interim Co-CEO role, clarifying executive accountability

Item EX-99.1 · Exhibit EX-99.1

  • Warren Foust appointed President and CEO, effective August 4, 2026, ending interim leadership
  • Foust adds Board seat after overseeing operational reset and return to profitable growth
  • Deborah Andrews becomes Executive Vice President while continuing as CFO, preserving finance leadership continuity
  • Management cites strongest first half in company history, China sequential growth, EVO+ launch, and favorable product-mix ASP tailwinds
  • Strategy remains centered on revenue growth, profit expansion, and innovation acceleration toward a multi-product portfolio

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other STAAR SURGICAL CO 8-K filings

Get the next STAA 8-K as it lands

Follow STAA for push alerts, or ask the research agent what this filing means.